Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Amyloid Fibrils03:03

Amyloid Fibrils

6.9K
6.9K
Amyloid Fibrils03:03

Amyloid Fibrils

12.8K
Amyloid fibrils are aggregates of misfolded proteins.  Under most circumstances, misfolded proteins are either refolded by chaperone proteins or degraded by the proteasome. However, in the case of a mutation or a disease, these proteins can accumulate to form large clusters and often further assemble to form elongated fibers, called fibrils. 
Amyloid deposits were observed as early as 1639 in the liver and the spleen.   In 1854, Rudolph Virchow performed iodine staining,...
12.8K
Alzheimer's Disease: Overview01:26

Alzheimer's Disease: Overview

2.0K
Alzheimer's Disease (AD) is a continually advancing neurodegenerative disorder, distinguished by escalating memory loss, cognitive dysfunction, and dementia. The disease unfolds in three stages: preclinical, mild cognitive impairment (MCI), and dementia. Its onset is insidious, and the progression gradual, with the cause not well explained by other disorders.
The clinical diagnosis of AD hinges on the presence of memory and other cognitive impairments. Biomarkers, such as changes in Aβ...
2.0K
Alzheimer's Disease: Treatment01:22

Alzheimer's Disease: Treatment

1.2K
Alzheimer's Disease (AD), a neurodegenerative disorder, is pathologically identified by amyloid plaques and neurofibrillary tangles composed of tau protein. AD pharmacotherapy aims to manage cognitive symptoms, delay disease progression, and treat behavioral symptoms. The treatment is primarily symptomatic and palliative, with no definitive disease-modifying therapy available. Cholinesterase inhibitors, including donepezil (Aricept), rivastigmine (Exelon), and galantamine (Razadyne), are...
1.2K
Dementia01:30

Dementia

663
Dementia is a collective term for cognitive disorders primarily affecting memory, thinking, and reasoning. It is not a specific disease but a syndrome, with Alzheimer's disease being the most common cause, accounting for approximately 60-80% of cases. Other types include vascular dementia, Lewy body dementia, and frontotemporal dementia. Dementia affects millions worldwide, particularly older adults, though it is not a normal part of aging.
The progression of dementia is generally gradual....
663
Ligand-Gated Ion Channel Receptor: Gating Mechanism01:30

Ligand-Gated Ion Channel Receptor: Gating Mechanism

4.6K
Ligand-gated ion channels are transmembrane proteins that play a vital role in intercellular communication and functions of the nervous system. They allow the influx of ions across the membrane once the neurotransmitter binds, allowing the subsequent transmission of electrical excitation across the neurons. Other ligand-gated ion channels, like the γ-aminobutyric acid (GABA) receptor, permit anions like chloride into the cells on the binding of the GABA molecule. Their entry into the cell...
4.6K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Amyloid PET Quantitation and Centiloid Thresholds in the Diagnosis of Alzheimer Disease: An Individual Participant Data Meta-Analysis.

JAMA·2026
Same author

Tau positron emission tomography analysis methods for the quantification of tau spread in preclinical and early Alzheimer's disease.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026
Same author

Impact of plasma pTau181 levels on clinician diagnostic confidence and management in memory and cognition clinics: A multi-site before-and-after study.

Alzheimer's & dementia (Amsterdam, Netherlands)·2026
Same author

Analysis of second-generation epigenetic clocks reveals further associations between disproportionate biological ageing and hippocampal volume.

GeroScience·2026
Same author

Predicting accumulation and age at onset of amyloid-β from genetic risk and resilience for Alzheimer's disease.

EBioMedicine·2026
Same author

Evidence for direct and sleep-moderated relationships between aquaporin-4 genetic variants and Alzheimer's disease phenotypes.

Alzheimer's & dementia : the journal of the Alzheimer's Association·2026

Related Experiment Video

Updated: Mar 21, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

1.0K

Amyloid PET Ligands for Dementia.

Victor L Villemagne1, Christopher C Rowe2

  • 1Department of Nuclear Medicine and Centre for PET, Austin Health, 145 Studley Road, Heidelberg, Victoria 3084, Australia; The Mental Health Research Institute of Victoria, 135 Oak Street, Parkville, Victoria 3052, Australia; Department of Medicine, Austin Health, Victoria 3084, Australia.

PET Clinics
|May 10, 2016
PubMed
Summary

Neurodegenerative diseases like Alzheimer's are age-dependent and characterized by amyloid plaques. Molecular imaging offers early diagnosis and monitoring of these conditions.

Keywords:
Alzheimer's diseaseAβBrain imagingPositron emission tomography

More Related Videos

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
08:25

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Published on: April 19, 2021

4.2K
Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
09:31

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

11.2K

Related Experiment Videos

Last Updated: Mar 21, 2026

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451
05:17

Hybrid PET/MRI Imaging of Alzheimer's Disease Based on 18F-AV-1451

Published on: April 18, 2025

1.0K
Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease
08:25

Detecting Amyloid-β Accumulation via Immunofluorescent Staining in a Mouse Model of Alzheimer's Disease

Published on: April 19, 2021

4.2K
Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry
09:31

Visualization of Amyloid β Deposits in the Human Brain with Matrix-assisted Laser Desorption/Ionization Imaging Mass Spectrometry

Published on: March 7, 2019

11.2K

Area of Science:

  • Neuroscience
  • Neuropathology
  • Molecular Biology

Background:

  • Neurodegeneration, particularly Alzheimer's disease (AD), is an age-dependent process causing synaptic failure and neuronal damage.
  • Current definitive diagnosis relies on postmortem brain examination, with hallmarks including neurofibrillary tangles and amyloid plaques.
  • The accumulation of β-amyloid (Aβ) is central to AD pathogenesis, driving research into molecular mechanisms and therapeutics.

Purpose of the Study:

  • To explore the role of β-amyloid (Aβ) accumulation in Alzheimer's disease (AD) pathogenesis.
  • To highlight the diagnostic limitations of current methods for neurodegenerative diseases.
  • To discuss the potential of molecular neuroimaging for early detection and monitoring of AD.

Main Methods:

  • Review of existing literature on neurodegeneration, AD pathology, and molecular imaging techniques.
  • Analysis of the role of β-amyloid (Aβ) in the development of Alzheimer's disease.
  • Examination of Positron Emission Tomography (PET) for in vivo assessment of molecular processes.

Main Results:

  • The progressive accumulation of β-amyloid (Aβ) is strongly implicated in Alzheimer's disease (AD) pathogenesis.
  • Molecular imaging, such as PET, enables in vivo detection of pathophysiological changes, including Aβ burden.
  • These techniques allow for early diagnosis at presymptomatic stages and monitoring of potential therapies.

Conclusions:

  • Understanding Aβ accumulation is key to developing new therapeutic strategies for AD.
  • Molecular neuroimaging offers a noninvasive approach for early and accurate diagnosis of AD and other dementias.
  • Advancements in imaging facilitate the evaluation and monitoring of disease-modifying therapies in neurodegenerative conditions.